Literature DB >> 25634435

Development of cerebral gray and white matter injury and cerebral inflammation over time after inflammatory perinatal asphyxia.

Hilde J C Bonestroo1, Cobi J Heijnen, Floris Groenendaal, Frank van Bel, Cora H Nijboer.   

Abstract

Antenatal inflammation is associated with increased severity of hypoxic-ischemic (HI) encephalopathy and adverse outcome in human neonates and experimental rodents. We investigated the effect of lipopolysaccharide (LPS) on the timing of HI-induced cerebral tissue loss and gray matter injury, white matter injury and integrity, and the cerebral inflammatory response. On postnatal day 9, mice underwent HI by unilateral carotid artery occlusion followed by systemic hypoxia which resulted in early neuronal damage (MAP2 loss) at 3 h that did not increase up to day 15. LPS injection 14 h before HI (LPS+HI) significantly and gradually aggravated MAP2 loss from 3 h up to day 15, resulting in an acellular cystic lesion. LPS+HI increased white matter damage, reduced myelination in the corpus callosum and increased white matter fiber coherency in the cingulum. The number of oligodendrocytes throughout the lineage (Olig2-positive) was increased whereas more mature myelinating (CNPase-positive) oligodendrocytes were strongly decreased after LPS+HI. LPS+HI induced an increased and prolonged expression of cerebral cytokines/chemokines compared to HI. Additionally, LPS+HI increased macrophage/microglia activation and influx of neutrophils in the brain compared to HI. This study demonstrates the sensitizing effect of LPS on neonatal HI brain injury for an extended time-frame up to 15 days postinsult. LPS before HI induced a gradual increase in gray and white matter deficits, including reduced numbers of more mature myelinating oligodendrocytes and a decrease in white matter integrity. Moreover, LPS+HI prolonged and intensified the cerebral inflammatory response, including cellular infiltration. In conclusion, as the timing of damage and/or involved pathways are changed when HI is preceded by inflammation, experimental therapies might require modifications in the time window, dosage or combinations of therapies for efficacious neuroprotection.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25634435     DOI: 10.1159/000368770

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  12 in total

1.  The Paradoxical Effects of Chronic Intra-Amniotic Ureaplasma parvum Exposure on Ovine Fetal Brain Development.

Authors:  Ruth Gussenhoven; Daan R M G Ophelders; Matthew W Kemp; Matthew S Payne; Owen B Spiller; Michael L Beeton; Sarah J Stock; Bertha Cillero-Pastor; Florian P Y Barré; Ron M A Heeren; Lilian Kessels; Bas Stevens; Bart P Rutten; Suhas G Kallapur; Alan H Jobe; Boris W Kramer; Tim G A M Wolfs
Journal:  Dev Neurosci       Date:  2017-08-29       Impact factor: 2.984

2.  C1 Esterase Inhibitor Reduces BBB Leakage and Apoptosis in the Hypoxic Developing Mouse Brain.

Authors:  Susan Jung; Hans-Georg Topf; Gudrun Boie; Regina Trollmann
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

3.  Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants.

Authors:  Matteo Bruschettini; Olga Romantsik; Alvaro Moreira; David Ley; Bernard Thébaud
Journal:  Cochrane Database Syst Rev       Date:  2020-08-19

4.  Melatonin Suppresses Toll Like Receptor 4-Dependent Caspase-3 Signaling Activation Coupled with Reduced Production of Proinflammatory Mediators in Hypoxic Microglia.

Authors:  Linli Yao; Pengfei Lu; Eng-Ang Ling
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

5.  Impact of neonatal hypoxia-ischaemia on oligodendrocyte survival, maturation and myelinating potential.

Authors:  Malgorzata Ziemka-Nalecz; Justyna Janowska; Lukasz Strojek; Joanna Jaworska; Teresa Zalewska; Malgorzata Frontczak-Baniewicz; Joanna Sypecka
Journal:  J Cell Mol Med       Date:  2017-08-07       Impact factor: 5.310

Review 6.  A Controversial Medicolegal Issue: Timing the Onset of Perinatal Hypoxic-Ischemic Brain Injury.

Authors:  Vittorio Fineschi; Rocco Valerio Viola; Raffaele La Russa; Alessandro Santurro; Paola Frati
Journal:  Mediators Inflamm       Date:  2017-08-13       Impact factor: 4.711

7.  Acute LPS sensitization and continuous infusion exacerbates hypoxic brain injury in a piglet model of neonatal encephalopathy.

Authors:  Kathryn A Martinello; Christopher Meehan; Adnan Avdic-Belltheus; Ingran Lingam; Sara Ragab; Mariya Hristova; Cally J Tann; Donald Peebles; Henrik Hagberg; Tim G A M Wolfs; Nigel Klein; Ilias Tachtsidis; Xavier Golay; Boris W Kramer; Bobbi Fleiss; Pierre Gressens; Nicola J Robertson
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

8.  Neuroinflammation and structural injury of the fetal ovine brain following intra-amniotic Candida albicans exposure.

Authors:  Daan R M G Ophelders; Ruth Gussenhoven; Martin Lammens; Benno Küsters; Matthew W Kemp; John P Newnham; Matthew S Payne; Suhas G Kallapur; Allan H Jobe; Luc J Zimmermann; Boris W Kramer; Tim G A M Wolfs
Journal:  J Neuroinflammation       Date:  2016-02-02       Impact factor: 8.322

9.  Hypoxic preconditioning improves long-term functional outcomes after neonatal hypoxia-ischemic injury by restoring white matter integrity and brain development.

Authors:  Ming-Yue Xu; Yang-Fan Wang; Peng-Ju Wei; Yan-Qin Gao; Wen-Ting Zhang
Journal:  CNS Neurosci Ther       Date:  2019-01-28       Impact factor: 5.243

10.  Intranasal Administration of Mesenchymal Stem Cell Secretome Reduces Hippocampal Oxidative Stress, Neuroinflammation and Cell Death, Improving the Behavioral Outcome Following Perinatal Asphyxia.

Authors:  Nancy Farfán; Jaime Carril; Martina Redel; Marta Zamorano; Maureen Araya; Estephania Monzón; Raúl Alvarado; Norton Contreras; Andrea Tapia-Bustos; María Elena Quintanilla; Fernando Ezquer; José Luis Valdés; Yedy Israel; Mario Herrera-Marschitz; Paola Morales
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.